PT - JOURNAL ARTICLE AU - Jorge Sepulveda AU - Lars F. Westblade AU - Susan Whittier AU - Michael J. Satlin AU - William G. Greendyke AU - Justin G. Aaron AU - Jason Zucker AU - Donald Dietz AU - Magdalena Sobieszczyk AU - Justin J. Choi AU - Dakai Liu AU - Kelvin Espinal AU - Sarah Russell AU - Dennis Camp AU - Charles Connelly AU - Daniel A. Green TI - Bacteremia and Blood Culture Utilization During COVID-19 Surge in New York City AID - 10.1101/2020.05.05.20080044 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.05.20080044 4099 - http://medrxiv.org/content/early/2020/05/06/2020.05.05.20080044.short 4100 - http://medrxiv.org/content/early/2020/05/06/2020.05.05.20080044.full AB - A surge of patients with coronavirus disease 2019 (COVID-19) presenting to New York City hospitals in March 2020 led to a sharp increase in the utilization of blood cultures, which overwhelmed the capacity of automated blood culture instruments. We sought to evaluate the utilization and diagnostic yield of blood cultures during the COVID-19 pandemic to determine prevalence and common etiologies of bacteremia, and to inform a diagnostic approach to relieve blood culture overutilization. We performed a retrospective cohort analysis of 88,201 blood cultures from 28,011 patients at a multicenter network of hospitals within New York City to evaluate order volume, positivity rate, time to positivity, and etiologies of positive cultures in COVID-19. Ordering volume increased by 34.8% in the second half of March 2020 compared to the first half of the month. The rate of bacteremia was significantly lower among COVID-19 patients (3.8%) than COVID-19 negative patients (8.0%) and those not tested (7.1%), p < 0.001. COVID-19 patients had a high proportion of organisms reflective of commensal skin microbiota, reducing the bacteremia rate to 1.6% when excluded. More than 98% of all positive cultures were detected within 4 days of incubation. Bloodstream infections are very rare for COVID-19 patients, which supports the judicious use of blood cultures in the absence of compelling evidence for bacterial coinfection. Clear communication with ordering providers is necessary to prevent overutilization of blood cultures during COVID-19 surges, and laboratories should consider shortening the incubation period from 5 days to 4 days to free additional capacity.Competing Interest StatementPotential conflicts of interest: J.J.C. has received research support from Roche Diagnostics. All other authors have no conflicts.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, DG, upon reasonable request.